PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-27.92%
Negative net income growth while GNPX stands at 13.75%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
3.10%
Less D&A growth vs. GNPX's 127.84%, reducing the hit to reported earnings. David Dodd would confirm that core assets remain sufficient.
No Data
No Data available this quarter, please select a different quarter.
-10.46%
Both cut yoy SBC, with GNPX at -40.62%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
292.72%
Well above GNPX's 200.20% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
215.28%
Lower AP growth vs. GNPX's 632.42%, indicating prompt payments. David Dodd would confirm no lost opportunity in interest-free credit if expansions are underfunded.
292.72%
Growth well above GNPX's 33.32%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
-67.58%
Both negative yoy, with GNPX at -58.11%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
-21.90%
Negative yoy CFO while GNPX is 11.19%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
-11.48%
Both yoy lines negative, with GNPX at -113.73%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-11.48%
We reduce yoy invests while GNPX stands at 433.82%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
No Data
No Data available this quarter, please select a different quarter.
-59.52%
Negative yoy issuance while GNPX is 121.34%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.